TECH Stock Analysis — Bio-Techne
Sector: Healthcare
AI Verdict
At 27.5x forward earnings, you’re betting the proprietary reagent moat delivers on a huge earnings leap—if not, the current price leaves little margin for error.
Competitive Moat
Bio-Techne supplies specialized proteins, antibodies, and reagents used in life sciences research and diagnostics, making it a critical supplier for labs and biotech firms. Its defensibility comes from proprietary manufacturing know-how and deep integration into customers’ experimental workflows, creating high switching costs.
Summary
A 275% jump in expected earnings next year has put Bio-Techne on the radar despite a sky-high trailing P/E.
Where It Stands
With a 33.51% 1-year return, an RSI of 85.3 signaling extreme overbought conditions, and a forward P/E of 27.5x (just above the healthcare median of 22x), the stock is priced for a major earnings rebound.
Key Metrics
- RSI: 85.3 — Overbought
- Trailing P/E: 102.9x
- Forward P/E: 27.5x
- PEG Ratio: 0.37
- Earnings Growth: +2.8%
- Revenue Growth: +0.0%
- Market Cap: $11.1B
- Dividend Yield: 0.00%
- 1-Year Return: 33.51%
- 52-Week High: $72.16
- 52-Week Low: $43.20
Analyst Consensus
16 Buy · 5 Hold · 1 Sell (22 analysts)
Bull Case
You’re paying 27.5x next year’s earnings for a consensus 275% EPS growth, which is cheap for that level of acceleration if the forecast holds.
Bear Case
If the forward P/E reverts to the sector median of 22x as the RSI cools off from 85.3, that’s a 20% downside just from multiple compression.
Catalyst to Watch
Watch for quarterly earnings—if the company misses on that 275% EPS growth expectation, the premium vanishes fast.